# A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

> **NCT06614855** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **James Markert, MD** · enrollment: 12 (estimated)

## Conditions studied

- Glioblastoma
- Glioblastoma (GBM)
- Astrocytoma
- Astrocytoma, Grade III
- Astrocytoma, Grade IV
- Gliosarcoma, Adult
- Gliosarcoma of Brain

## Interventions

- **DRUG:** C134
- **DRUG:** C134

## Key facts

- **NCT ID:** NCT06614855
- **Lead sponsor:** James Markert, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614855, "A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06614855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*